Of note, the in vivo disruption of the Sp1/NFκB association in a mouse model for KIT-driven leukemia results in a strong inhibition of leukemogenesis and suggests that the targeting of the miR-29b/Sp1/NFκb regulatory loop represents a viable therapeutic option in AML [30]. This evidence concerns the gene SP1 and leukemia.